Evidence map›Paper›PMID 37652206›Full record

Observational studyKidney international2023

The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events.

Steven Menez, Yumeng Wen, Leyuan Xu, Dennis G Moledina, Heather Thiessen-Philbrook, David Hu, Wassim Obeid, Pavan K Bhatraju, T Alp Ikizler, Edward D Siew and 10 more

Open access · hybridAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Kidney international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 26 citations in OpenAlex.

  1. Plasma Biomarkers of Kidney Tubule Health during Ambulatory AKI and Kidney Function Recovery in SPRINT.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Trial
  2. Associations of Urine Biomarkers During Ambulatory Acute Kidney Injury With Subsequent Recovery in Kidney Function: Findings From the SPRINT Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025
    Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 2 countries.

Steven MenezDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yumeng WenDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Leyuan XuSection of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Dennis G MoledinaSection of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Heather Thiessen-PhilbrookDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David HuDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Wassim ObeidDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Pavan K BhatrajuDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA; Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.
T Alp IkizlerDivision of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Edward D SiewDivision of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Vernon M ChinchilliDepartment of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Amit X GargDivision of Nephrology, Department of Medicine, Western University, London, Ontario, Canada.
Alan S GoDivision of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Kathleen D LiuDivision of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
James S KaufmanDivision of Nephrology, New York University School of Medicine, New York, New York, USA; Divison of Nephrology, VA New York Harbor Healthcare System, New York, New York, USA.
Paul L KimmelNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA; National Institutes of Health, Bethesda, Maryland, USA.
Jonathan HimmelfarbKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Steven G CocaDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Lloyd G CantleySection of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Chirag R ParikhDivision of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: chirag.parikh@jhmi.edu.
Johns Hopkins University · USYale University · USUniversity of Washington · USVanderbilt University Medical Center · USIcahn School of Medicine at Mount Sinai · USKaiser Permanente · USNational Institutes of Health · USPennsylvania State University · USUniversity of California, San Francisco · USVA NY Harbor Healthcare System · USWestern University · CA

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3M
Data Coordinating Center for the Natural History of AKI ConsortiumU01DK082183 · NIDDK · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI CHINCHILLI, VERNON M · 2008 to 2018
$9.7M
Novel Kidney Injury Tools in Deceased Organ Donation to Predict Graft OutcomesR01DK093770 · NIDDK · YALE UNIVERSITY · PI Chirag R Parikh · 2012 to 2026
$9.5M
Vanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, MATTHEW H · 2017 to 2021
$5.9M
Progression of Acute Kidney Injury to Chronic Kidney DiseaseU01DK082185 · NIDDK · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2008 to 2017
$5.1M
Impact of Acute Kidney Injury on Kidney Disease ProgressionU01DK082192 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI IKIZLER, TALAT ALP · 2008 to 2018
$5.0M
Post-Discharge Nephrology Follow-up for Improved OutcomesU01DK129984 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Chirag R Parikh · 2021 to 2026
$4.2M
Prospective Evaluation of Acute Kidney Injury (PEAK) CohotU01DK082223 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2008 to 2018
$4.0M
Macrophage Function in Kidney RepairR01DK093771 · NIDDK · YALE UNIVERSITY · PI LLOYD G CANTLEY · 2012 to 2026
$3.9M
Acute kidney injury among patients with chronic kidney diseaseR01DK114014 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 2018 to 2021
$3.0M
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL085757NIDDK NIH HHS K01 DK120783NIDDK NIH HHS K23 DK100468NIDDK NIH HHS K23 DK117065NIDDK NIH HHS K23 DK128538NIDDK NIH HHS P30 DK079310NIDDK NIH HHS P30 DK114809NIDDK NIH HHS R01 DK093770NIDDK NIH HHS R01 DK093771NIDDK NIH HHS R01 DK098233NIDDK NIH HHS R01 DK101507NIDDK NIH HHS R01 DK114014NIDDK NIH HHS R01 DK126815NIDDK NIH HHS R01 DK128087NIDDK NIH HHS R03 DK111881NIDDK NIH HHS U01 DK082183NIDDK NIH HHS U01 DK082185NIDDK NIH HHS U01 DK082192NIDDK NIH HHS U01 DK082223NIDDK NIH HHS U01 DK114866NIDDK NIH HHS U01 DK129984NIDDK NIH HHS UH3 DK114866
6 · The paper itself

Abstract

Biomarkers of tubular function such as epidermal growth factor (EGF) may improve prognostication of participants at highest risk for chronic kidney disease (CKD) after hospitalization. To examine this, we measured urinary EGF (uEGF) from samples collected in the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study, a multi-center, prospective, observational cohort of hospitalized participants with and without AKI. Cox proportional hazards regression was used to investigate the association of uEGF/Cr at hospitalization, three months post-discharge, and the change between these time points with major adverse kidney events (MAKE): CKD incidence, progression, or development of kidney failure. Clinical findings were paired with mechanistic studies comparing relative Egf expression in mouse models of kidney atrophy or repair after ischemia-reperfusion injury. MAKE was observed in 20% of 1,509 participants over 4.3 years of follow-up. Each 2-fold higher level of uEGF/Cr at three months was associated with decreased risk of MAKE (adjusted hazards ratio 0.46, 95% confidence interval: 0.39-0.55). Participants with the highest increase in uEGF/Cr from hospitalization to three-month follow-up had a lower risk of MAKE (adjusted hazards ratio 0.52; 95% confidence interval: 0.36-0.74) compared to those with the least change in uEGF/Cr. A model using uEGF/Cr at three months combined with clinical variables yielded moderate discrimination for MAKE (area under the curve 0.73; 95% confidence interval: 0.69-0.77) and strong discrimination for kidney failure at four years (area under the curve 0.96; 95% confidence interval: 0.92-1.00). Accelerated restoration of Egf expression in mice was seen in the model of adaptive repair after injury, compared to a model of progressive atrophy. Thus, urinary EGF/Cr may be a biomarker of distal tubular health, with higher concentrations and increased uEGF/Cr post-discharge independently associated with reduced risk of MAKE in hospitalized patients.

Indexed as

Acute Kidney InjuryRenal Insufficiency, ChronicAftercareAnimalsAtrophyBiomarkersEpidermal Growth FactorGlomerular Filtration RateHumansKidneyMicePatient DischargeProspective StudiesBiomarkersEpidermal Growth Factoracute kidney injurybiomarkerschronic kidney disease

Identifiers

PMID37652206
PMCPMC10840723
OpenAlexW4386258329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.